title: Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela.
abstract: BACKGROUND
  This study assessed the feasibility, performance, and safety of Mirasol®-treated platelet concentrates (M-PC) stored for up to 7 days.
  
  
  METHODS
  This prospective observational study was approved by the ethical committee of the University Clinic of Santiago de Compostela. Informed consent was asked from patients receiving M-PC. M-PCs were treated with the Mirasol system according to the manufacturer's instructions. Thrombocytopenic patients were transfused according to the Spanish transfusion guidelines. Post-transfusion platelet counts were measured at 1 h and/or 24 h after transfusion. Post-transfusion surveillance of patients was maintained during the study.
  
  
  RESULTS
  Data from 54 evaluable patients and 135 transfusions were analyzed. The mean age of patients was 58 years. The mean age of M-PC at transfusion was 3.6 days. The mean platelet dose was 3.7 × 1011. The transfusion responses measured as mean corrected count increment 1 h after transfusion (CCI1h) and CCI24hwere 9,659 and 4,751, respectively. 65% of transfusions resulted in CCI1hvalues ≥ 7,500. 51% of transfusions resulted in CCI24hvalues ≥ 4,500.
  
  
  CONCLUSIONS
  The use of M-PC in the supportive treatment proved to be safe and effective for this cohort of thrombocytopenic patients.
authors.affiliation: University Clinic of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: M Dolores
authors.initials: MD
authors.lastname: Vilariño
authors.affiliation: Blood Transfusion Center of Galicia, Santiago de Compostela, Spain.
authors.forename: Azucena
authors.initials: A
authors.lastname: Castrillo
authors.affiliation: University Clinic of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Campos
authors.affiliation: Terumo BCT Europe, Zaventem, Belgium.
authors.forename: Rachel
authors.initials: R
authors.lastname: Kilian
authors.affiliation: University Clinic of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Villamayor
authors.affiliation: Terumo BCT Europe, Zaventem, Belgium.
authors.forename: Marcia
authors.initials: M
authors.lastname: Cardoso
keywords: Clinical performance; Pathogen reduction; Riboflavin-based pathogen reduction